148 related articles for article (PubMed ID: 30813708)
81. Immunohistochemical study of nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 in invasive breast carcinoma of no special type.
Symonowicz K; Duś-Szachniewicz K; Woźniak M; Murawski M; Kołodziej P; Osiecka B; Jurczyszyn K; Ziółkowski P
Exp Ther Med; 2014 Oct; 8(4):1039-1046. PubMed ID: 25187794
[TBL] [Abstract][Full Text] [Related]
82. Relationships of nuclear, architectural and International Federation of Gynecology and Obstetrics grading systems in endometrial cancer.
Toptaş T; Peştereli E; Bozkurt S; Erdoğan G; Şimşek T
J Turk Ger Gynecol Assoc; 2018 Mar; 19(1):17-22. PubMed ID: 29072178
[TBL] [Abstract][Full Text] [Related]
83. Immunohistochemical expression of hormone receptors, Ki-67, endoglin (CD105), claudins 3 and 4, MMP-2 and -9 in endometrial polyps and endometrial cancer type I.
Peres GF; Spadoto-Dias D; Bueloni-Dias FN; Leite NJ; Elias LV; Domingues MAC; Padovani CR; Dias R
Onco Targets Ther; 2018; 11():3949-3958. PubMed ID: 30022838
[TBL] [Abstract][Full Text] [Related]
84. EPPK1 as a Prognostic Biomarker in Type I Endometrial Cancer and Its Correlation with Immune Infiltration.
Liu L; Yuan S; Yao S; Cao W; Wang L
Int J Gen Med; 2024; 17():1677-1694. PubMed ID: 38706750
[TBL] [Abstract][Full Text] [Related]
85. Relationship between Ribosomal Protein S6-pS240 Expression and other Prognostic Factors in Non-Special Type Invasive Breast Cancer.
Cuperjani F; Gashi L; Kurshumliu F; Dreshaj S; Selimi F
Breast Care (Basel); 2019 Jun; 14(3):171-175. PubMed ID: 31316316
[TBL] [Abstract][Full Text] [Related]
86. Assessing Metabolic Risk Factors for LVSI in Endometrial Cancer: A Cross-Sectional Study.
Lin Q; Lu Y; Lu R; Chen Y; Wang L; Lu J; Ye X
Ther Clin Risk Manag; 2022; 18():789-798. PubMed ID: 35971461
[TBL] [Abstract][Full Text] [Related]
87. Significance of HER2 and VEGFR2 in Early-stage Endometrial Cancer.
An HJ; Song DH; Kim YM; Jo HC; Baek JC; Park JE
In Vivo; 2022; 36(2):723-730. PubMed ID: 35241527
[TBL] [Abstract][Full Text] [Related]
88. Reconstruction of Immune Microenvironment and Signaling Pathways in Endometrioid Endometrial Adenocarcinoma During Formation of Lymphovascular Space Involvement and Lymph Node Metastasis.
Cheng Y; Zhang X; Wang Z; Wang J
Front Oncol; 2020; 10():595082. PubMed ID: 33363026
[TBL] [Abstract][Full Text] [Related]
89. α-Fetoprotein-Producing Endometrial Carcinoma Is Associated With Fetal Gut-Like and/or Hepatoid Morphology, Lymphovascular Infiltration,
Otani T; Murakami K; Shiraishi N; Hagiyama M; Satou T; Matsuki M; Matsumura N; Ito A
Front Med (Lausanne); 2021; 8():799163. PubMed ID: 34977100
[TBL] [Abstract][Full Text] [Related]
90. Computer-Aided Diagnosis Parameters of Invasive Carcinoma of No Special Type on 3T MRI: Correlation with Pathologic Immunohistochemical Markers.
Jeong J; Park CS; Lee JW; Kim K; Kim HS; Jun SY; Oh SJ
Taehan Yongsang Uihakhoe Chi; 2022 Jan; 83(1):149-161. PubMed ID: 36237358
[TBL] [Abstract][Full Text] [Related]
91. Tumor Characteristic Variations between Symptomatic and Asymptomatic Endometrial Cancer.
Vinklerová P; Bednaříková M; Minář L; Felsinger M; Hausnerová J; Ovesná P; Weinberger V
Healthcare (Basel); 2021 Jul; 9(7):. PubMed ID: 34356280
[TBL] [Abstract][Full Text] [Related]
92. Correlation of PD-L1 immunohistochemical expression with microsatellite instability and p53 status in endometrial carcinoma.
Arafa M; Shebl AM; Salama A; ElZahaf E; Ashamallah SA; Foda AA; Awad AE; Shalaby A
Eur J Obstet Gynecol Reprod Biol X; 2022 Dec; 16():100172. PubMed ID: 36440057
[TBL] [Abstract][Full Text] [Related]
93. The analysis of hormonal status and vascular and cell proliferation in endometrioid endometrial adenocarcinomas.
Drocaş I; Crăiţoiu Ş; Stepan AE; Iliescu DG; Drocaş IA; Stepan MD
Rom J Morphol Embryol; 2022; 63(1):113-120. PubMed ID: 36074674
[TBL] [Abstract][Full Text] [Related]
94. Unexpected location of endometrial adenocarcinoma - a case report.
Poenaru MO; Pleş L; Sima RM; Ionescu P; Florescu C; Neacşu I; Stănică CD; Neacşu A
Rom J Morphol Embryol; 2020; 61(3):941-945. PubMed ID: 33817738
[TBL] [Abstract][Full Text] [Related]
95. Elevated CA-125 Level and ER-Negative as Prognostic Factors for Ovarian Metastasis in Patients with Endometrial Cancer: A Retrospective Cohort Study.
Ling X; Zheng Z; Xu J; Xu G; Zhou H; Lin Z; Li Y; Liang J; Lu H
Med Sci Monit; 2020 Dec; 26():e928826. PubMed ID: 33361739
[TBL] [Abstract][Full Text] [Related]
96. Potential Role for a Panel of Immunohistochemical Markers in the Management of Endometrial Carcinoma.
Salama A; Arafa M; ElZahaf E; Shebl AM; Awad AAE; Ashamallah SA; Hemida R; Gamal A; Foda AA; Zalata K; Abdel-Hady EM
J Pathol Transl Med; 2019 May; 53(3):164-172. PubMed ID: 30813708
[TBL] [Abstract][Full Text] [Related]
97. Expression of ER, PR, C-erbB-2 and Ki-67 in Endometrial Carcinoma and their Relationships with the Clinicopathological Features.
Yu CG; Jiang XY; Li B; Gan L; Huang JF
Asian Pac J Cancer Prev; 2015; 16(15):6789-94. PubMed ID: 26434913
[TBL] [Abstract][Full Text] [Related]
98. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
[TBL] [Abstract][Full Text] [Related]
99. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M; Zhao L; Shen D; Li X; Wang J; Wei L
Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
[TBL] [Abstract][Full Text] [Related]
100. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
